-
Mashup Score: 37
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limit…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
PURPOSE Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation of CDK4/6i with endocrine therapy beyond initial tumor progression or if the addition of checkpoint inhibitor therapy has value in this setting. METHODS The randomized multicenter phase II PACE trial enrolled patients with hormone receptor–positive/HER2– MBC whose disease had progressed on previous CDK4/6i and aromatase inhibitor (AI) therapy. Patients were randomly assigned 1:2:1 to receive fulvestrant (F), fulvestrant plus palbociclib (F + P), or fulvestrant plus palbociclib and avelumab (F + P + A). The primary end point was investigator-assessed progression-free survival (PFS) in patients treated with F versus F + P. RESULTS Overall, 220 patients were randomly assigned between September 2017
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial - 3 month(s) ago
This article reports an analysis of clinical outcomes using predicted modeling of circulating tumor cells to stratify stage IV disease. Results suggest the need
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16
mor DNA is a promising blood-based biomarker that is prognostic in several malignancies. Detection of ctDNA by NGS may provide insights regarding the mutational profiles in PDAC to help guide clinical decisions for patients in a potentially curative setting. However, the utility of ctDNA as a biomarker in localized PDAC remains unclear. Methods: Patients with localized PDAC were enrolled in a prospective study at Northwestern Medicine between October 2020 and October 2022. Blood samples were collected to perform targeted tumor agnostic NGS utilizing the Tempus x|F 105 gene panel at three timepoints: pre-therapy (at diagnosis), post-NAC, and after local therapy, including surgery. The relationship between ctDNA detection and CA19-9, and the prognostic significance of ctDNA detection were analyzed. Results: 56 patients were included in the analysis. ctDNA was detectable in 48% at diagnosis, 33% post-NAC, and 41% after local therapy. After completion of NAC, patients with detectable ctDNA
Source: journals.lww.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? - 5 month(s) ago
Despite a significant evolution in treatment strategies for early breast cancer (EBC) patients, up to 30% of them experience recurrence due to occult …
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications - 7 month(s) ago
The human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Background although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clinical practice. Methods The study analyzed a multi-institutional cohort comprising 703 patients with luminal-like MBC characterized for circulating tumor DNA through next generation sequencing (NGS). Pathway classification was defined based on previous work (i.e., RTK, RAS, RAF, MEK, NRF2, ER, WNT, MYC, P53, cell cycle, notch, PI3K). Single nucleotide variations (SNVs) were annotated for their oncogenicity through OncoKB. Only pathogenic variants were included in the models. Associations among clinical characteristics, pathway classification, and ESR1/PIK3CA codon variants were explored. Results The results showed a differential pattern of associations for ESR1 and PIK3CA codon variants in terms of co-occurring pathway alterations patterns of metastat
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The immunogram of inflammatory breast cancer - 10 month(s) ago
Inflammatory breast cancer (IBC) is the most aggressive and fatal clinical presentation of breast cancer. Despite the term “inflammatory”, based on th…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Copy number aberrations in ctDNA enables prognosis prediction and molecular characterization of breast cancer - 12 month(s) ago
AbstractBackgrounds. Low-pass whole-genome sequencing (LP-WGS)-based circulating tumor DNA (ctDNA) analysis is a versatile tool for somatic copy number aberrati
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases | New England Journal of Medicine https://t.co/jVVpW3KW7u Continued de-escalation of local therapies in breast cancer.